Dose finding study with irinotecan (CPT-11) in previously treated colo-rectal cancer

被引：0
|
作者：
Viéitez, JM
Carrasco, J
Fra, J
Muñiz, I
Esteban, E
Palacio, I
Sala, M
Puertas, J
Estrada, E
Buesa, JM
Lacave, AJ
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [21] A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy
    Kakolyris, S
    Souglakos, J
    Kouroussis, C
    Koukourakis, M
    Kalbakis, K
    Mavroudis, D
    Vardakis, N
    Georgoulias, V
    ANTICANCER RESEARCH, 2002, 22 (03) : 1891 - 1896
  • [22] A CASE-CONTROL STUDY OF DIET AND COLO-RECTAL CANCER
    JAIN, M
    COOK, GM
    DAVIS, FG
    GRACE, MG
    HOWE, GR
    MILLER, AB
    INTERNATIONAL JOURNAL OF CANCER, 1980, 26 (06) : 757 - 768
  • [23] Pharmacokinetics and dose optimization of selenomethionine (SLM) as an adjunct to irinotecan (CPT-11) therapy.
    Smith, PF
    Fakih, M
    Pendyala, L
    Prey, J
    Azrak, R
    Creaven, P
    Rustum, YM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P31 - P31
  • [24] A combination phase I study of amrubicin and irinotecan (CPT-11) in patients with lung cancer.
    Kurata, T
    Kaneda, H
    Tamura, K
    Satoh, T
    Nogami, T
    Uejima, H
    Nakagawa, K
    Fukuoka, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 703S - 703S
  • [25] A dose finding study of biweekly administration of irinotecan (CPT-11), 5-fluorouracil (5-FU) and levofolinic acid (I-LV) in colorectal cancer
    Casaretti, R
    Catalano, G
    Comella, P
    De Vita, F
    Avallone, V
    Gravina, A
    Orditura, M
    Comis, S
    Faranda, A
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 68 - 68
  • [26] Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients
    Slatter, JG
    Schaaf, LJ
    Sams, JP
    Feenstra, KL
    Johnson, MG
    Bombardt, PA
    Cathcart, KS
    Verburg, MT
    Pearson, LK
    Compton, LD
    Miller, LL
    Baker, DS
    Pesheck, CV
    Lord, RS
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (04) : 423 - 433
  • [27] Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer
    Sugiyama, T
    Yakushiji, M
    Nishida, T
    Ushijima, K
    Okura, N
    Kigawa, J
    Terakawa, N
    CANCER LETTERS, 1998, 128 (02) : 211 - 218
  • [28] Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer
    Quintela-Fandino, M
    Gravalos, C
    Gonzalez, E
    Garcia-Velasco, A
    Cortés-Funes, H
    ANTI-CANCER DRUGS, 2005, 16 (01) : 31 - 38
  • [29] A pilot study of high-dose focal radiotherapy and concurrent irinotecan (CPT-11) followed by intravenous BCNU plus CPT-11 for children with diffuse intrinsic brainstem gliomas
    Larrier, N.
    Gururangan, S.
    Halperin, E.
    NEURO-ONCOLOGY, 2007, 9 (02) : 206 - 207
  • [30] Final result of phase II study of irinotecan (CPT-11) plus oral S-1 for previously treated advanced NSCLC patients.
    Arai, Daisuke
    Soejima, Kenzo
    Naoki, Katsuhiko
    Ikemura, Shinnosuke
    Terai, Hideki
    Sato, Takashi
    Satomi, Ryousuke
    Nakayama, Souhei
    Yoda, Satoshi
    Ishioka, Kouta
    Ohgino, Keiko
    Miyata, Jun
    Kabata, Hiroki
    Miyazaki, Masaki
    Betsuyaku, Tomoko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345